BL22 immunotoxin

DRUG4 trials

Sponsors

National Cancer Institute (NCI), MedImmune LLC

Conditions

LeukemiaLymphoma

Phase 1

BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

WithdrawnNCT00024115

National Cancer Institute (NCI)Leukemia, Lymphoma

Updated: 2015-04-28

Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia

CompletedNCT00021983

National Cancer Institute (NCI)Leukemia

Start: 1998-12-31Updated: 2015-04-29

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

SuspendedNCT00077493

MedImmune LLCLeukemia, Lymphoma

Start: 2004-01-31End: 2008-10-31Target: 95Updated: 2007-12-28

BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

CompletedNCT00126646

MedImmune LLCLeukemia, Lymphoma

Start: 2005-06-30End: 2009-06-30Target: 24Updated: 2010-06-22

Related Papers

Soluble CD22 as a tumor marker for hairy cell leukemia.

2008-07-0224 citations